Literature DB >> 17935833

Perspectives on genetic animal models of serotonin toxicity.

Allan V Kalueff1, Justin L LaPorte, Dennis L Murphy.   

Abstract

Serotonin syndrome, or serotonin toxicity, is a serious disorder attributable to exaggerated serotonergic function in the brain, most commonly after antidepressant overdose or after combining several psychotropic medications. Similar condition (serotonin syndrome-like behavior) can be evoked in animals experimentally, following administration of serotonergic drugs. In addition to pharmacological stimulation, some genetic and other factors may contribute to serotonin toxicity, prompting the need for new experimental genetic models relevant to this disorder. Here we discuss current problems and perspectives regarding genetic animal models of serotonin-related syndromes, and outline the potential utility of these models in experimental neurochemistry and clinical research.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17935833     DOI: 10.1016/j.neuint.2007.08.015

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  3 in total

Review 1.  Zebrafish as an emerging model for studying complex brain disorders.

Authors:  Allan V Kalueff; Adam Michael Stewart; Robert Gerlai
Journal:  Trends Pharmacol Sci       Date:  2014-01-09       Impact factor: 14.819

Review 2.  How the serotonin story is being rewritten by new gene-based discoveries principally related to SLC6A4, the serotonin transporter gene, which functions to influence all cellular serotonin systems.

Authors:  Dennis L Murphy; Meredith A Fox; Kiara R Timpano; Pablo R Moya; Renee Ren-Patterson; Anne M Andrews; Andrew Holmes; Klaus-Peter Lesch; Jens R Wendland
Journal:  Neuropharmacology       Date:  2008-09-11       Impact factor: 5.250

3.  Two cases of mild serotonin toxicity via 5-hydroxytryptamine 1A receptor stimulation.

Authors:  Hiroto Nakayama; Sumiyo Umeda; Masashi Nibuya; Takeshi Terao; Koichi Nisijima; Soichiro Nomura
Journal:  Neuropsychiatr Dis Treat       Date:  2014-02-11       Impact factor: 2.570

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.